Effect of HER2-Neu expression in primary tumor on the efficacy of adjuvant polychemotherapy in patients with stage i-ii small cell lung cancer


Cite item

Full Text

Abstract

Lung cancer is a "world leader" in structure incidence and mortality from malignant disease. Surgery is the main treatment that can completely treat patient. But, nearly 50% of patients had disease progression after operation due to presents of micro metastases in time of operation. That’s why necessary to indicate group of patients who needs adjuvant chemotherapy for increasing survival of patients. It is possible to indicate group of patients with the help of molecular markers. The aim of our study is to investigate effectiveness of adjuvant chemotherapy in early non-small cell lung cancer patients due to expression of HER2-Neu in primary tumor. Evaluation of HER2-Neu expression was conducted in 243 patients. HER2-Neu hyperexpression was detected in 70 (28,8%) patients, and absence of HER2-Neu expression in 173 patients (71,2%). We did not identify relationships between HER2-Neu expression in primary tumor and sex, age of patients, location, histologic form, morphologic differentiation of tumor, T criteria. However, patients with N1 and accordingly stage II more frequently defined HER2-Neu hyper expression (р=0,0001 and р=0,001). Moreover, decrease survival was defined in patients with early stages non-small cell lung cancer with HER2-Neu hyper expression in primary tumor (р<0,0001). There is a significant effect after adjuvant chemotherapy in patients with low HER2-Neu expression. It helps to individualize adjuvant chemotherapy and avoid groundless toxic therapy prescription.

About the authors

A. P Kolesnik

Zaporozhye State Medical University

Email: kap_kan@mail.ru
канд. мед. наук, доц. каф. онкологии г. Запорожье

References

  1. Araujo A., Ribeiro R., Azevedo I. et al. Genetic polymorphisms of the epidermal growth factor and related receptor in Non-Small-Cell Lung Cancer. A review of the literature. Oncologist. 2007; 12: 201-10.
  2. Garcia M., Jemal A., Ward E.M., Center M.M., Hao Y., Siegel R.L., Thun M.J. Global cancer facts & figures 2007. Atlanta, GA: American Cancer Society; 2007.
  3. Proctor R.N. Commentary: Schairer and Schoniger’s forgotten tobacco epidemiology and the Nazi quest for racial purity. Int. J. Epidemiol. 2001; 30: 31-4.
  4. Spasova I. Adjuvant chemotherapy in the treatment of non-small cell lung cancer. Cas. Lek. Cesk. 2007; 146(4): 329-36.
  5. Chang M.Y., Mentzer S.J., Colson Y.L. et al. Factors predicting poor survival after resection of stage IA non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 2007; 134: 850-6.
  6. Sadasiwan C., Medendorp S., Sreedhar R., Raji A., Blum M., De-Hoyas A., Patel J., Yeldandi A. Prognostic role of VEGF, EGFR, COX-2, cERB-b2 and ER-alpha in stage 1 non-small cell lung cancers. ASCO Meeting Abstr. 2007; 25: 7696.
  7. Silvestri G.A., Tanoue L.T., Margolis M.L. The noninvasive staging of non-small cell lung cancer. Chest. 2003; 123: 147-56.
  8. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P. et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med. 2004; 350: 351-60.
  9. Douillard J.Y., Rosell R., Delena M. et al. ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association. J. Clin. Oncol. 2005: 23: 624s.
  10. Strauss G.M., Herndon J., Maddaus M.A. et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) protocol 9633. J. Clin. Oncol. 2004; 22: 621s.
  11. Filipits M., Pirker R., Dunant A. et al. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: The International Adjuvant Lung Cancer Trial Biologic Program. J. Clin. Oncol. 2007; 25: 2735-40.
  12. Ikeda N., Nagase S., Ohiro T. Individualized adjuvant chemotherapy for surgically resected lung cancer and the roles of biomarkers. Ann. Thorac. Cardiovasc. Surg. 2009; 15(3): 144-9.
  13. Эллиниди В. Н. Практическая иммуногистоцитохимия. СПб.: ВЦЭРМ МЧС России; 2002.
  14. Boenisch T., Farmilo A.J., Stead R.H. Immunohistochemical staining methods: Handbook. 3rd ed. Carpinteria: Dako Cytomation Corporation; 2001.
  15. Gold K.A., Lee J.J., Ping Y. et al. Biologic risk model for recurrence in resected early-stage non-small cell lungcancer (ES NSCLC). J. Clin. Oncol. 2011; 29(15): 7053.
  16. Winton T., Livingston R., Johnson D. et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N. Engl. J. Med. 2005; 352: 2589-97.
  17. Onn A., Choe D.H., Herbst R.S. et al. Tumor cavitation in stage I non-small cell lung cancer: Epidermal growth factor receptor expression and prediction of poor outcome. Radiology. 2005; 237: 342-7.
  18. Суховерша О.А. Патоморфологічні фактори прогнозу як основа оптимізації лікування ІІІА стадії недрібноклітинного раку легень. Морфологія. 2007; 1(4): 100-7.
  19. Moldvay J., Scheid Ph., Wild P. et al. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma. Clin. Cancer Res. 2000; 6: 1125-34.

Copyright (c) 2013 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies